• Genomics-driven personalization and pharmacogenomics translation focus on turning genetic variation and drug response data into individualized therapies, evaluating effectiveness, cost-effectiveness, and real-world implementation in clinical care [1], [2], [9], [12].

• System-level integration: building an enabling ecosystem with education, informatics, and health economics to move from discovery to scalable personalized care, addressing barriers like EMR integration and policy considerations [3], [8], [10], [20], [19].

• Ethical, philosophical, and policy framing of personalized medicine, including identity of terms, ethical issues, frameworks for understanding its scope, and implications for practice and governance [13], [14], [16], [17].

• Biomarker-driven and disease-focused personalization including cardiovascular and osteoarthritis contexts, nanomedicine, and autoimmune/inflammatory disease personalization, highlighting clinical utility and translational pathways [6], [15], [5], [18].